Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ex-JPMA Secretary General Expresses Hope for Globalization of Domestic Pharma Industry: JPLA Seminar
December 7, 2012
- ARB Market Nearing Its Limit; No More Growth in the Second Half?
December 7, 2012
- MSD Submits NDA for Novel Insomnia Treatment Suvorexant
December 6, 2012
- Lantus Shows Low Incidence of Hypoglycemia in Combination Use with OHA: Sanofi
December 5, 2012
- Astellas Initiates Patient Enrollment in PII Trial of Tivozanib for Triple Negative Breast Cancer
December 5, 2012
- US Merck Initiates Multinational PII/III Study for BACE Inhibitor for Alzheimer’s Disease
December 5, 2012
- Pediatric NDA for AcipHex Granted Priority Review by US FDA: Eisai
December 4, 2012
- Hospira Applies for Irinotecan Generic for Pediatric Malignant Solid Tumors Based on Data from the Public Domain
December 4, 2012
- Novartis Concludes Comarketing Agreement with Taisho for SGLT-2 Inhibitor Luseogliflozin
December 4, 2012
- Sanwa Kagaku, Kowa Launch DPP-4 Inhibitor Suiny on November 30
December 3, 2012
- Novartis AG Receives First Approval for Cell-Culture Influenza Vaccine in the US
December 3, 2012
- Fast-growing Plavix Could Become Japan’s No. 1 Ethical Drug by Next Year
December 3, 2012
- US FDA Accepts NDA Filing for Tivozanib: Astellas
November 30, 2012
- CMIC MPSS to Offer Comprehensive Region-Wide CSO Service for Long-Listed Drugs
November 30, 2012
- China’s Drug Costs to Expand to 11 Trillion Yen in 2030 by 5% Annual Growth: UtoBrain
November 29, 2012
- Long-Listed Products to Be Switched to Combination Drugs, Original Drugs Rather than Generics: President Sawai
November 29, 2012
- Sawai to Seek Alternative Suppliers for All of Its Products
November 29, 2012
- Santen Files Anti-Allergic Ophthalmic Solution DE-114
November 29, 2012
- Chugai, Nippon Shinyaku Conclude Codevelopment, Comarketing Agreement for Anti-CD20 Antibody
November 29, 2012
- Takeda to Establish Medical Affairs Department within Development Division
November 28, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…